top of page

REPROCELL, IBM and STFC announce successful completion of AI project





NETPark tenants, REPROCELL has announced the launch of a new commercial service upon completion of one of the first EXCELERATE projects to be delivered by the Hartree National Centre for Digital Innovation (HNCDI), via a partnership between the Science and Technology Facilities Council (STFC) and IBM. Through EXCELERATE, REPROCELL has collaborated with HNCDI to create a machine learning (ML) platform that simplifies and accelerates the analysis of big data from drug development studies.


The ground-breaking platform will be used as part of a new service, Pharmacology-AI, to help researchers identify which interindividual differences have the largest influence on drug response or related clinical outcomes. Conventional analysis of big data can be very time-consuming and require significant expertise; Pharmacology-AI removes some of the obstacles facing those who wish to use big data in their research. It is hoped the service will enable Pharma to design clinical trials that are more successful and cost less, by identifying patient populations most likely to benefit from new drugs much earlier in the drug development process. The software can also be used to reveal why some patients respond to commonly prescribed drugs, while other patients gain little or no benefit.


Pharmacology-AI is unique in its ability to quickly reveal the genomic or clinical features driving drug response,” said Graeme Macluskie, Director of Precision Medicine at REPROCELL. “We’re excited to see what insights the platform can offer to clients developing early-stage precision medicine strategies” he continued.


Clinical and drug response data is more challenging to process via machine learning due to its high dimensionality” said Peter Waggett, Director of Research at IBM. “IBM and STFC have worked closely with REPROCELL to develop the Pharmacology-AI platform, whose results correlate with real-world data.”


This project is just one example of how artificial intelligence can be used to generate long-term societal and economic impact” said Professor Kate Royse, Director of STFC. “The benefits of machine learning are not just limited to the technology sector and could help many different industries across the UK” she continued.


If you would like to learn more about Pharmacology-AI, you can find information about this service on the REPROCELL website.

Comments


Other Science, engineering & technology news

bottom of page